Sebastian veterinarian performs stem cell treatment for pets

SEBASTIAN Toby, a 6-year-old golden retriever, loves to run and play catch. And Oreo, a 12-year-old border collie mix, also is a bundle of energy.

Movement for both dogs got easier about a month ago when they received a revolutionary stem cell treatment at the Highlands Animal Hospital.

Veterinarian Marcus Kramer performed the successful transplant procedures, which were developed by Kentucky-based MediVet-America.

Both dogs had been in significant pain with a restricted range of motion, as shown on X-rays.

“It’s made a big difference,” said Kramer. “The really amazing thing is that they both healed so quickly. Both dogs had problems with their hips and were suffering from osteoarthritis. Just 30-days later, they are able to walk and run again.”

Adult animal stem cell technology uses the pet’s own regenerative healing power to treat dogs, cats and horses suffering from arthritis, hip dysplasia and tendon, ligament and cartilage injuries. Under anesthesia, Kramer removed about 40 grams of fat from each dog and separated the stem cells from the fat. He then activated the stem cells under an LED light, and injected them back into the dogs.

Stem cell therapy allows an animal to get off pain and anti-inflammatory drugs, Kramer said. MediVet-America’s therapy is done entirely at the animal hospital in about three hours, and costs about $1,800 for dogs and $2,400 for horses. That compares to thousands of dollars that pet owners could expect to pay for medication over a pet’s lifetime.

Erica Kent, a spokesman for MediVet-America, said using the LED light is integral to the patented-process, because the light helps to awaken stem cells and makes them more active. The three-color light stimulates millions of dormant cells to initiate repair from the moment the cells are injected into the animal’s body, according to the MediVet-America website.

The company is also offering a program that allows pet owners to bank stem cells when animals are younger to use if their pet develops illnesses like arthritis in old age.

STEM CELL THERAPY

Read more from the original source:
Sebastian veterinarian performs stem cell treatment for pets

Posted in Pet Stem Cell Therapy | Tagged , , , , , , , , , , | Comments Off

Nanoparticles may pose environmental threat

(ISNS) — No longer the stuff of science fiction, nanoparticles are becoming more and more common. The extremely tiny objects can do just about everything, from filtering pollution to delivering medicine in the body. However, no one is sure of the effects if they get loose in the environment.

A team of scientists from the National Institute of Standards and Technology and the University of Massachusetts at Amherst thinks there may be something to worry about.

They have not proven the particles are dangerous, but have shown that some nanoparticles can be absorbed into plants and mutate the plant’s DNA, and that, they say, is worth a further look.

Nanoparticles are so small that they act as a bridge between the size of atoms and something of tangible substance. The thickness of a human hair is measured in millionths of a meter; nanoparticles, in billionths of a meter.

And now, they are everywhere. Manufacturers put them in clothing such as socks to kill bacteria. They are in a type of house paint that cleans itself in sunlight and in the coating on eyeglasses. Clear sunscreen lotion now on the market contains zinc or titanium nanoparticles. Cars will soon have paint that heals itself from scratches.

Nanoparticles have become so common it is assumed inevitably they will end up in the environment.

To see what would happen to plants exposed to nanoparticles, the researchers took particles of copper oxide and exposed three kinds of plants to them: radishes and two types of rye, the researchers reported in Environmental Science & Technology.

They chose nanoparticles of copper because they are widely used for coloring glass, in ceramics, as a polish and in the manufacturing of rayon. They also are used in the electronics industry to manufacture semiconductors, said Bryant Nelson of the National Institute of Standards and Technology.

The research team also used particles of copper oxide larger than nano-size as a comparison as well as regular copper ions.

Copper oxide is an oxidizing agent, and some oxidizing agents from metals can cause cancer in humans, a reason for the concern.

Original post:
Nanoparticles may pose environmental threat

Posted in Nano medicine | Tagged , , , , , , , | Comments Off

MetLife Foundation recognizes Alzheimer's disease research with prestigious awards

Public release date: 15-May-2012 [ | E-mail | Share ]

Contact: Dennis Tartaglia dtartaglia@tartagliacommunications.com 732-545-1848 Tartaglia Communications

MetLife Foundation today announced the recipients of its 2012 Awards for Medical Research in Alzheimer’s Disease: Clifford R. Jack Jr., M.D., professor of Radiology and The Alexander Family Professor of Alzheimer’s Disease Research at Mayo Clinic (Rochester, MN), and Christine Van Broeckhoven, Ph.D. D.Sc., professor and department director of the VIB Department of Molecular Genetics at the University of Antwerp (Belgium). In addition, Randall J. Bateman, M.D., associate professor of Neurology at the Washington University School of Medicine in St. Louis, is recipient of MetLife Foundation’s Promising Investigator Award.

Dr. Jack, an innovator in clinical studies of brain structure in disease, developed and applied imaging methodologies to determine and track the stages of Alzheimer’s disease. Dr. Van Broeckhoven, a basic scientist and expert in molecular genetics, has made groundbreaking discoveries establishing the genetic basis of inherited Alzheimer’s disease and related disorders. Dr. Bateman, a neurologist and biochemist, has pioneered the use of measurements of beta-amyloid protein in the brain to better understand the biochemical basis of this illness.

The winners were recognized at a scientific briefing and awards ceremony today in New York.

“MetLife Foundation is proud to present these awards that recognize outstanding achievements in medical research,” said Dennis White, president and chief executive officer, MetLife Foundation. “Doctors Jack, Van Broeckhoven and Bateman have made significant contributions to our understanding of Alzheimer’s disease and their dedication helps bring us closer to finding a cure for Alzheimer’s disease.”

About the Awards

Now in their 26th year, the awards provide outstanding researchers with an opportunity to freely pursue new ideas. At the heart of the program is a belief in research as the road to understanding and ultimately treating this devastating disease. Each major award recipient receives a $200,000 research grant for his or her institution to further their work, and a personal prize of $50,000. The recipient of the Promising Investigator Award receives a $100,000 grant to his institution to further his work in Alzheimer’s disease. MetLife Foundation established the awards in 1986 to recognize and reward scientists demonstrating significant contributions to the understanding of Alzheimer’s disease.

The MetLife Awards for Medical Research in Alzheimer’s Disease are managed by the American Federation for Aging Research (AFAR). Founded in 1981, AFAR has championed the cause and supported the funding of science in healthier aging and age-related medicine.

“We have selected these individuals because of their novel and significant approaches to Alzheimer’s disease, which are paving the way for additional discoveries that are important for diagnosis and treatments for this disease,” said Donald L. Price, M.D., chair of the MetLife Awards for Research in Alzheimer’s Disease Advisory Committee, which selected the winners. Dr. Price, professor of Pathology, Neurology and Neuroscience, Johns Hopkins School of Medicine, is a previous recipient of the MetLife Award.

More here:
MetLife Foundation recognizes Alzheimer's disease research with prestigious awards

Posted in Molecular Genetics | Tagged , , , , , , , , , | Comments Off

ESIM announces ‘Excellence in Integrative Medicine Research Awards’

Published on May 14, 2012 at 8:26 AM

The European Society for Integrative Medicine (ESIM), with support from Heel, announces a new international research prize in integrative medicine: the “Excellence in Integrative Medicine Research Award.” Applicants are asked to submit papers by May 30, 2012.

“This international research prize recognizes innovative and outstanding scientific papers in the field of integrative medicine, thus fostering collaboration between conventional and complementary medicine,” emphasizes Dr. Ghassan Andraos, Head of Global Medicine at Biologische Heilmittel Heel GmbH.

The ESIM research prize is awarded in two categories: one for clinical investigations, the other for basic research. Each of the two winners will be awarded the sum of 10, 000 euros. Submissions must be based on a scientific manuscript that has either already been published in a peer-reviewed journal in 2011 or 2012 or has been accepted for publication. The jury, which is made up of a selection of international experts in integrative medicine, will rate the papers according to three criteria: innovation, level of relevance and scientific excellence.

The winners of the “Excellence in Integrative Medicine Research Awards” will be announced at the 5th annual European Conference on Integrative Medicine (ECIM) to be held in Florence, Italy from September 21 to 22.

Source: European Society for Integrative Medicine

Read more here:
ESIM announces ‘Excellence in Integrative Medicine Research Awards’

Posted in Integrative Medicine | Tagged , , , , , , , , , , , , , | Comments Off

Integrative Medicine Part II — Health Care of the Future

Is it possible that health care can become more effective, more personalized, more attuned to real health and wellness in a manner that truly benefits you the customer?

At the recent health and wellness conference celebrating the 20th anniversary of the University of Maryland Center for Integrative Medicine there was a panel discussion moderated by Center director Brian Berman, MD on the topic of health care of the future. Here are some excerpts from the comments made by Dr. Delia Chiaramonte, Dr. Jeff Bland and myself.

The first question was what are the problems with the health care system today? Here are some of the responses: There is excellent research and innovation along with superb providers in this country. But the delivery system is dysfunctional and to date America has tolerated this dysfunction. Its a medical care not a health care system. The emphasis is strongly on disease management and not disease prevention or health promotion. American medical care is very expensive, about $8,000 per capita and yet outcomes are not what they could or should be. For example, America does not have the lowest infant mortality rate nor the longest life span. Other developed countries beat us on both counts. Medical care of acute illness is generally quite good in the United States but chronic diseases of which there are more and more occurring are not well cared for. The system is provider oriented rather than patient oriented and the patient is not the real customer.

There is a shortage of primary care physicians and this is getting worse every year. Only 30% of American physicians are primary care physicians compared to about 70% in most other developed countries. Those still in primary care practice have inadequate understanding of the causes and prevention of chronic diseases. And too few appreciate the importance of care coordination nor the full range of non-pharmacologic options for care.

The second question was what can patients do to get the best possible health care? Among the responses, here are a few: Since today the patient is largely not the customer of the doctor, a good place to start is to change that paradigm. A high deductible health policy means that the patient will now be paying the primary care physician directly for care and thus this changes the professional-client relationship to a more normal occurrence. The physician will now become more attentive, allocate more time, offer more preventive care and will coordinate the care of chronic illnesses.

Individuals also need to take more responsibility for their health and wellness directly. Attention to nutrition, exercise, stress and tobacco are key first steps. Work place wellness programs can materially assist. They can offer a health care premium deduction in return for engaging in added educational programs to improve lifestyles.

Social networking can have an increasingly beneficial effect. Lifestyle changes are easier to accomplish in a peer group setting. Usually we think of this as a physical group setting but it can also be done through the use of social media. Groups help give a positive reinforcement for behavior change.

Social networking through sites such as Facebook, Twitter or You Tube or others can be used to leverage the medical care delivery system to become more patient centered, more effective at the coordination of chronic illness, more attuned to prevention and responsive to true integrated medicine.

Everyone should have a primary care physician, one well schooled in the most current evidence-based care approaches yet who is attuned to the full gamut of integrative medical approaches such as chiropractic, nutrition, personal training, massage therapy, and acupuncture. You need to be sure that your primary care physician will spend the time needed to deal with health and wellness and not just disease. You may well need to pay your primary care physician directly rather than buy insurance but the primary care physician will then be financially able to offer you the time you really need and deserve.

The third question was what will the health care provider of the future be like and how will integrative medicine contribute to health care in the future? This question was addressed in an earlier post; go to this link.

Continue reading here:
Integrative Medicine Part II — Health Care of the Future

Posted in Integrative Medicine | Tagged , , , , , , , , , , , , , | Comments Off

Heel Supports New International Research Prize in Integrative Medicine

BADEN-BADEN, Germany–(BUSINESS WIRE)–

The European Society for Integrative Medicine (ESIM), with support from Heel, announces a new international research prize in integrative medicine: the Excellence in Integrative Medicine Research Award. Applicants are asked to submit papers by May 30, 2012.

This international research prize recognizes innovative and outstanding scientific papers in the field of integrative medicine, thus fostering collaboration between conventional and complementary medicine, emphasizes Dr. Ghassan Andraos, Head of Global Medicine at Biologische Heilmittel Heel GmbH.

The ESIM research prize is awarded in two categories: one for clinical investigations, the other for basic research. Each of the two winners will be awarded the sum of 10, 000 euros. Submissions must be based on a scientific manuscript that has either already been published in a peer-reviewed journal in 2011 or 2012 or has been accepted for publication. The jury, which is made up of a selection of international experts in integrative medicine, will rate the papers according to three criteria: innovation, level of relevance and scientific excellence.

The winners of the Excellence in Integrative Medicine Research Awards will be announced at the 5th annual European Conference on Integrative Medicine (ECIM) to be held in Florence, Italy from September 21 to 22. For more information, visit: www.ecim-congress.org.

The mission of the European Society for Integrative Medicine is to promote science, research, education and further training, support for medical care and providing advice on policy in the realm of integrative medicine. For these purposes, the Society organizes scientific events and encourages dialog with health-care authorities and institutions.

Heel is a pharmaceutical company that develops, manufactures and distributes medicines based on natural substances. As the global leader in homeopathic combination preparations, the company is also a pioneer in the field of scientific research in natural healthcare. In cooperation with academic institutions, Heel actively fosters the concept of integrative medicine and is building the bridge between homeopathy and conventional medicine to improve patient care and health.

Biologische Heilmittel Heel GmbH, with corporate headquarters located in Baden-Baden/Germany and a staff of 1,300, achieved an annual turnover of 196 million euros in 2011 70 percent of it outside of Germany. Heel medicinesare available through subsidiaries and distribution partners in over 50 countries around the world. www.heel.com

See original here:
Heel Supports New International Research Prize in Integrative Medicine

Posted in Integrative Medicine | Tagged , , , , , , , , , | Comments Off

Cancer Genetics IPO Faces Facebook

Cancer Genetics is pursuing a strategy that differs from Facebook’s IPO plan, expert says.

A Rutherford, N.J.-based start-up developing tools to diagnose cancer is planning to launch an initial public offering this week under the long shadow of Facebook’s long-awaited blockbuster IPO.

Cancer Genetics Inc. is looking to raise more than $50 million with an initial public offering of 4 million shares priced between $11 to $13 a share.

The offering comes as the IPO market is struggling back toward its pre-recession level of activity, although it remains well below the peak of the dot-com fueled boom of the 1990s. If Cancer Genetics prices this week, it will be the first IPO in North Jersey since Park Ridge-based SeaCube Container Leasing Ltd. went public in October 2010. The ticker symbol would be CGIX, and the shares would trade on the Nasdaq Stock Market.

How the Facebook IPO will affect that of Cancer Genetics is unclear. David Menlow, president of IPOfinancial.com, said he thinks it “greatly hampers their chance of success.”

“Investors are not interested in paying attention to anything other than the 800-ton gorilla in the room,” which is Facebook, he said.

But Jay R. Ritter, a professor of finance at University of Florida in Gainesville, who tracks IPOs, said the two companies are playing to different investors.

Cancer Genetics, which is planning its IPO for Friday, is looking to attract institutional investors interested in holding company stock for the long period it takes for a biotech company to make a medical breakthrough, he said. In contrast, many Facebook investors are mainly interested in the chance of making a quick profit if the stock takes off, he said.

“Facebook is getting huge amounts of attention,” Ritter said. “Lots of investors are coming out of the woodwork who do not have an interest in buying biomedical companies.”

Cancer Genetics, founded in 1999, is focused on developing and commercializing tests and services to diagnose, predict and help treat hematological, urogenital and HPV-associated cancers. The top executives at Cancer Genetics are Chairman Raju S.K. Chaganti, Chief Executive Officer Panna L. Sharma and Elizabeth A. Czerepak, chief financial officer.

View original post here:
Cancer Genetics IPO Faces Facebook

Posted in Genetics | Tagged , , , , , , , , , , , , , , | Comments Off

Schizophrenia’s core genetic features proposed

Researchers may be closing in on diseases inherited component

Web edition : 1:40 pm

Schizophrenias elusive genetic roots may finally be within grasp. A new, wide-ranging effort has uncovered a set of DNA signatures that are shared by people with the disease consistently enough that the set can be used to reliably predict whether someone has the disease. If replicated, the results may point out ways to diagnose schizophrenia and suggest new targets for treatment.

By analyzing a battery of 542 genetic variants, researchers could predict who had schizophrenia in a group of European Americans and African Americans. The confirmation of the result in people of varying ancestry suggests that the set of genes truly does detect the core features of the disorder, scientists report online May 15 in Molecular Psychiatry.

Genetic studies in psychiatry tend to produce initial excitement but are then not reproduced in independent populations, which is the most important proof that a finding is solid and real, says study coauthor Alexander Niculescu of the Indiana University School of Medicine in Indianapolis.

Niculescu and his colleagues created their gene panel by assessing a slew of earlier studies on schizophrenia: Data from humans and animals on gene variation and gene behavior all fed into the teams analysis. If a gene popped out of several different datasets, the reasoning went, it is probably important to schizophrenia. Niculescu compares this method called convergent functional genomics to an Internet search: The more links to a web page, the higher it comes up on your search list.

After sifting through all of this data, the team identified some top candidates, some already known to be related to schizophrenia (DISC1, a known culprit, sits at the top of the list) and a handful that have never before been linked to the disease.

Continued here:
Schizophrenia’s core genetic features proposed

Posted in Genetic Medicine | Tagged , , , , , , , , , , , , , , | Comments Off

Lung cancer molecular subtypes correlate with genetic alterations, patient's response to therapy

Published on May 14, 2012 at 12:51 AM

Cancer therapies targeting specific molecular subtypes of the disease allow physicians to tailor treatment to a patient’s individual molecular profile. But scientists are finding that in many types of cancer the molecular subtypes are more varied than previously thought and contain further genetic alterations that can affect a patient’s response to therapy.

A UNC-led team of scientists has shown for the first time that lung cancer molecular subtypes correlate with distinct genetic alterations and with patient response to therapy. These findings in pre-clinical models and patient tumor samples build on their previous report of three molecular subtypes of non-small cell lung cancer and refines their molecular analysis of tumors.

Their findings were published in the May 10, 2012 online edition of the Public Library of Science One.

Study senior author, Neil Hayes, MD, MPH, associate professor of medicine, says, “It has been known for about a decade of using gene expression arrays that “molecular subtypes” exist. These subtypes have molecular “fingerprints” and frequently have different clinical outcomes. However, the underlying etiologies of the subtypes have not been recognized. Why do tumors form subtypes?

“Our study shows that tumor subtypes have different underlying alterations of DNA as part of the difference. These differences are further evidence of the importance of subtypes and the way we will use them. For example, the mutations are different which may imply much more ability to target than previously recognized. Also, we are starting to get a suggestion that these subtypes may reflect different cells of origin that rely on different cancer pathways. This is further unlocking the diversity of this complex disease.” Hayes is a member of UNC Lineberger Comprehensive Cancer Center.

The team first defined and reported in 2006 on three lung cancer molecular subtypes, named according to their genetic pattern – bronchoid, squamoid and magnoid.

In this PLoS One paper they sought to determine if distinct genetic mutations co-occur with each specific molecular subtypes. They found that specific genetic mutations were associated with each subtype and that these mutations may have independent predictive value for therapeutic response.

Source: University of North Carolina School of Medicine

Read the rest here:
Lung cancer molecular subtypes correlate with genetic alterations, patient's response to therapy

Posted in Genetic Medicine | Tagged , , , , , , , , , , , , | Comments Off

Genetic test can accurately predict spread of eye cancer

Researchers at Washington University School of Medicine in St. Louis have developed a genetic test that can accurately predict whether the most common form of eye cancer will spread to other parts of the body, particularly the liver.

In 459 patients with ocular melanoma at 12 centers in the United States and Canada, the researchers found the test could successfully classify tumors more than 97 percent of the time.

The study will appear in an upcoming issue of the journal Ophthalmology, but is now online.

“When the cancer spreads beyond the eye, it’s unlikely any therapy is going to be effective,” says principal investigator J. William Harbour, MD. “But it’s very possible that we can develop treatments to slow the growth of metastatic tumors. The real importance of this test is that by identifying the type of tumor a patient has, we can first remove the tumor from the eye with surgery or radiation and then get those individuals at high risk into clinical trials that might be able to help them live longer.”

Harbour believes the test should allow ocular oncologists to quickly evaluate the risks associated with particular tumors and to begin treatment the moment they can detect any spread of the cancer.

Melanoma of the eye is relatively rare, diagnosed in about 2,000 people in the United States each year. Advances in treatment have allowed surgeons to preserve patients’ vision, but when cancer spreads beyond the eye, it often is deadly.

About a decade ago, Harbour, the Paul A. Cibis Distinguished Professor of Ophthalmology and Visual Sciences, began using gene expression profiling to monitor the activity of thousands of genes in and around ocular melanoma tumors.

“At the time, we were surprised to see that based on these gene expression profiles, the tumors clustered into two groups that corresponded, almost perfectly, to patients whose cancer spread and those whose cancer was confined within the eye,” says Harbour, who directs Washington University’s Center for Ocular Oncology. “Tumors with a class 1 gene expression profile, or ‘signature,’ very rarely spread, but those with a class 2 profile frequently develop into metastatic cancer.”

Initially, Harbour’s group identified differences in approximately 1,000 genes between class 1 and class 2 tumors, but they whittled down that number, hoping to develop a simple test that could be used easily by ophthalmologists. Eventually, they settled on about a dozen genes that could be evaluated in tumor samples collected with a needle biopsy.

“We went through a number of sophisticated algorithms and validations, and we came up with a group of 12 genes,” he says. “We also included three more genes that don’t change whether they are in tumor tissue or healthy tissue. Those genes act as our ‘controls’ in this prognostic test.”

See the article here:
Genetic test can accurately predict spread of eye cancer

Posted in Genetic Medicine | Tagged , , , , , , , , , , | Comments Off